A Randomized, Double-Blind, Parallel Pharmacokinetic Study Comparing the Trastuzumab Biosimilar Candidate, Aryotrust®, and Reference Trastuzumab in Healthy Subjects Publisher Pubmed



Farmahini Farahani M^{1, 2} ; Maghzi P^{1, 2} ; Jafari Aryan N^{1, 2} ; Payandemehr B³ ; Soni M⁴ ; Azhdarzadeh M^{2, 5} Show Affiliations
Source: Expert Opinion on Investigational Drugs Published:2020

Abstract

Background: AryoTrust® (AryoGen Pharmed Co., Iran) is a biosimilar candidate for the EU-sourced reference trastuzumab, Herceptin®. This study was designed to evaluate the bioequivalence between AryoTrust® and Herceptin®. Research design and methods: In this double-blind, parallel study, 60 healthy male subjects were randomized 1:1 to receive a single dose of AryoTrust® or Herceptin® (6 mg/kg) as intravenous infusion. The primary endpoint of the study was the area under the concentration versus time to infinity (AUC0-inf), and the main secondary endpoints were maximum measured concentration (Cmax), area under the concentration versus time from zero to the last quantifiable concentration time (AUC0-last), immunogenicity, and safety. Results: Sixty subjects were enrolled in the study and baseline demographics were similar between the two groups. The two groups demonstrated similar pharmacokinetic parameters and the 90% confidence interval (CI) for primary and secondary endpoints were within the bioequivalence acceptance range (80.00%–125.00%). No serious adverse event or immunogenicity was reported, and all of the adverse events reported were mild and similar between the two treatment groups. Conclusion: AryoTrust® was well tolerated, had a similar safety profile to reference trastuzumab, and its pharmacokinetic bioequivalence was confirmed. Trial registration: The trial is registered at Indian Trials Registry (CTRI/2019/03/018218). © 2020 Informa UK Limited, trading as Taylor & Francis Group.